Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.

Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.

3C Study Collaborative Group None., (2018), Am J Transplant, 18, 1424 - 1434

Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.

Hacke W. et al, (2018), Int J Stroke, 13, 175 - 189

Interpretation of the evidence for the efficacy and safety of statin therapy.

Collins R. et al, (2016), Lancet, 388, 2532 - 2561

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839

Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.

Lees KR. et al, (2016), Stroke, 47, 2373 - 2379

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.

Whiteley WN. et al, (2016), Lancet Neurol, 15, 925 - 933

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.

Cholesterol Treatment Trialists' (CTT) Collaboration None., (2016), Am Heart J, 176, 63 - 69

Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial

(2015), The Lancet Neurology, 14, 485 - 496

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2015), Lancet, 385, 1397 - 1405

Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.

Lindley RI. et al, (2015), Stroke, 46, 746 - 756

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

Emberson J. et al, (2014), Lancet, 384, 1929 - 1935

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

3C Study Collaborative Group None. et al, (2014), Lancet, 384, 1684 - 1690

Efficacy of aspirin in people with diabetes: an individual participant data meta-analysis of 26 randomised trials

Wong CX. et al, (2014), EUROPEAN HEART JOURNAL, 35, 1020 - 1020

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.

Herrington W. et al, (2014), Clin J Am Soc Nephrol, 9, 914 - 919

Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.

Stroke Thrombolysis Trialists' Collaborative Group None., (2013), Int J Stroke, 8, 278 - 283

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

Haynes R. et al, (2013), Transplant Res, 2

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaborators None. et al, (2012), Lancet, 380, 581 - 590

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group None. et al, (2012), Lancet, 379, 2352 - 2363

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Wardlaw JM. et al, (2012), The Lancet, 379, 2364 - 2372

Load More

Include forthcoming?